Payment overview · 2025
General Payments
$313.33
11 reported records · 7 companies
Healthcare provider profile · identity verified
Hakop Oganyan, M.D.
Allopathic & Osteopathic Physicians|General Practice · NORTH HOLLYWOOD, CA · NPI 1366472045
Verified facts
What the public records show
CMS Open Payments records show Hakop Oganyan, M.D. received $313.33 in general payments during 2025 across 11 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Spravato, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Spravato by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $69.31 | 22.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $67.78 | 21.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $52.94 | 16.9% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $45.00 | 14.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $34.05 | 10.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.28 | 8.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.97 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $313.33 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $69.31 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $52.94 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $45.00 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $35.50 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $32.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 65 | exact normalized | Medicare Part D |
| SPRAVATO spravato |
2025 | Spravato | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
114 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 213 | 32 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 210 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 189 | 31 |
| Alendronate Sodium | Alendronate Sodium | 160 | 18 |
| Ezetimibe | Ezetimibe | 154 | 21 |
| Ibuprofen | Ibuprofen | 152 | 23 |
| Gabapentin | Gabapentin | 151 | 20 |
| Metformin Er Gastric | Metformin Hcl | 151 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 19 |
| Clonidine Hcl | Clonidine Hcl | 133 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 119 | 37 |
| Linzess | Linaclotide | 114 | 19 |
| Atorvastatin Calcium | Atorvastatin Calcium | 112 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 103 | 12 |
| Memantine Hcl Er | Memantine Hcl | 101 | 13 |
| Losartan Potassium | Losartan Potassium | 98 | 13 |
| Meclizine Hcl | Meclizine Hcl | 95 | 15 |
| Alprazolam | Alprazolam | 89 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 88 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | suppressed |
| Lovastatin | Lovastatin | 77 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 77 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | suppressed |
| Furosemide | Furosemide | 73 | suppressed |
| Hydrocortisone | Hydrocortisone | 73 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 72 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 13 |
| Ssd | Silver Sulfadiazine | 69 | suppressed |
| Tavaborole | Tavaborole | 66 | suppressed |
| Celecoxib | Celecoxib | 65 | 16 |
| Rexulti | Brexpiprazole | 65 | 13 |
| Mirtazapine | Mirtazapine | 64 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | suppressed |
| Simvastatin | Simvastatin | 63 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 58 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 54 | suppressed |
| Gemtesa | Vibegron | 54 | suppressed |
| Carvedilol | Carvedilol | 52 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 51 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 49 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 47 | 11 |
| Rivastigmine | Rivastigmine | 47 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 47 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Fluocinonide | Fluocinonide | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Lisinopril | Lisinopril | 38 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 37 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Cyclosporine | Cyclosporine | 28 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Ibu | Ibuprofen | 27 | suppressed |
| Spravato | Esketamine Hcl | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 18 |
| Calcipotriene | Calcipotriene | 24 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Cialis | Tadalafil | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Lumigan | Bimatoprost | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $313.33 · 11 records | E.R. Squibb & Sons, L.L.C. | AUSTEDO XR, COBENFY, REXULTI, SPRAVATO, TRINTELLIX, UZEDY, VIVITROL, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error